Landos Biopharma Inc. (LABP)
Landos Biopharma Statistics
Share Statistics
Landos Biopharma has 3.13M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 3.13M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.33M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.05 and the forward PE ratio is null. Landos Biopharma's PEG ratio is 0.02.
| PE Ratio | -1.05 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.72 |
| P/FCF Ratio | -1.12 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Landos Biopharma has an Enterprise Value (EV) of -14.58M.
| EV / Sales | 0 |
| EV / EBITDA | 0.64 |
| EV / EBIT | 0.71 |
| EV / FCF | 0.71 |
Financial Position
The company has a current ratio of 6.09, with a Debt / Equity ratio of 0.
| Current Ratio | 6.09 |
| Quick Ratio | 6.09 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -69% and Return on Invested Capital is -71.49%.
| Return on Equity | -69% |
| Return on Assets | -57.66% |
| Return on Invested Capital | -71.49% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.15M |
| Employee Count | 19 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 3.52% in the last 52 weeks. The beta is 0.14, so Landos Biopharma's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | 3.52% |
| 50-Day Moving Average | 19.89 |
| 200-Day Moving Average | 8.25 |
| Relative Strength Index (RSI) | 77.26 |
| Average Volume (20 Days) | 27.04K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -22.73M |
| Net Income | -21.93M |
| EBITDA | -22.73M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.5 |
Balance Sheet
The company has 37.55M in cash and 0 in debt, giving a net cash position of 37.55M.
| Cash & Cash Equivalents | 37.55M |
| Total Debt | 0 |
| Net Cash | 37.55M |
| Retained Earnings | -155.36M |
| Total Assets | 29.9M |
| Working Capital | 23.15M |
Cash Flow
In the last 12 months, operating cash flow was -20.48M and capital expenditures 0, giving a free cash flow of -20.48M.
| Operating Cash Flow | -20.48M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.48M |
| FCF Per Share | -3.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LABP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -95.5% |
| FCF Yield | -89.15% |
Analyst Forecast
Currently there are no analyst rating for LABP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 26, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | May 26, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -3.17 |
| Piotroski F-Score | 2 |